hat
LGD-4033 se yon modulator récepteurs selektif (SARMS), ak yon woman ki pa esteroyidal SARM oral ki mare AR ak segondè afinite (Ki nan ~ 1 nM) ak selektivite. Li nan yon klas nan reseptè Androjenèn (AR) ligand ki se tisi selektif, devlope nan trete misk gaspiye ki asosye ak kansè, maladi egi ak kwonik ak pèt nan misk laj ki gen rapò. LGD-4033 espere pwodwi benefis yo ki ka geri nan testostewòn ak sekirite amelyore, tolerabilite ak akseptasyon pasyan akòz tisi-selektif mekanis nan aksyon ak yon wout oral nan administrasyon yo.
eng
LGD-4033 is a selective androgen receptor modulator (SARMS), and a novel non-steroidal oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It's in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.